SLP Stock Overview
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Simulations Plus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.00 |
| 52 Week High | US$52.69 |
| 52 Week Low | US$32.69 |
| Beta | 0.71 |
| 1 Month Change | 10.52% |
| 3 Month Change | 17.53% |
| 1 Year Change | 11.19% |
| 3 Year Change | -30.29% |
| 5 Year Change | 102.55% |
| Change since IPO | 3,245.45% |
Recent News & Updates
Recent updates
Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price
Mar 29
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Feb 09Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI
Feb 01We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit
Jan 12Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Nov 06Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Sep 06Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Jun 28Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Feb 10With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case
Nov 23A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Oct 21Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Sep 19Simulations Plus goes ex-dividend tomorrow
Jul 21Simulations Plus Q3 2022 Earnings Preview
Jul 05Simulations Plus (NASDAQ:SLP) Might Be Having Difficulty Using Its Capital Effectively
Jun 08Estimating The Fair Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Mar 02Simulations Plus: Software For The Pharma Industry, Significant Upside Potential
Mar 01This Is Why We Think Simulations Plus, Inc.'s (NASDAQ:SLP) CEO Might Get A Pay Rise Approved By Shareholders
Feb 05Be Wary Of Simulations Plus (NASDAQ:SLP) And Its Returns On Capital
Jan 18Are Simulations Plus, Inc. (NASDAQ:SLP) Investors Paying Above The Intrinsic Value?
Nov 24The Returns On Capital At Simulations Plus (NASDAQ:SLP) Don't Inspire Confidence
Oct 11Calculating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Aug 17Simulations Plus: Growth Speculation, Buy The Dip In This Drug Testing Company
Aug 01Shareholder Returns
| SLP | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 2.9% | 1.0% | 1.2% |
| 1Y | 11.2% | -7.4% | 24.7% |
Return vs Industry: SLP exceeded the US Healthcare Services industry which returned -7.4% over the past year.
Return vs Market: SLP underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| SLP volatility | |
|---|---|
| SLP Average Weekly Movement | 8.8% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLP has not had significant price volatility in the past 3 months.
Volatility Over Time: SLP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 195 | Shawn O'Connor | www.simulations-plus.com |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Simulations Plus, Inc. Fundamentals Summary
| SLP fundamental statistics | |
|---|---|
| Market cap | US$919.31m |
| Earnings (TTM) | US$10.52m |
| Revenue (TTM) | US$64.67m |
87.4x
P/E Ratio14.2x
P/S RatioIs SLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLP income statement (TTM) | |
|---|---|
| Revenue | US$64.67m |
| Cost of Revenue | US$16.08m |
| Gross Profit | US$48.59m |
| Other Expenses | US$38.08m |
| Earnings | US$10.52m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 75.14% |
| Net Profit Margin | 16.26% |
| Debt/Equity Ratio | 0% |
How did SLP perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield46%
Payout RatioDoes SLP pay a reliable dividends?
See SLP dividend history and benchmarks| Simulations Plus dividend dates | |
|---|---|
| Ex Dividend Date | Apr 26 2024 |
| Dividend Pay Date | May 06 2024 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 11 days |
Does SLP pay a reliable dividends?
See SLP dividend history and benchmarks